SANNA, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.173
EU - Europa 769
AS - Asia 112
AF - Africa 1
Totale 2.055
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.170
PL - Polonia 493
IE - Irlanda 89
SE - Svezia 69
IT - Italia 50
HK - Hong Kong 38
VN - Vietnam 32
CN - Cina 22
CH - Svizzera 13
FI - Finlandia 13
DE - Germania 12
GB - Regno Unito 12
TR - Turchia 7
SG - Singapore 5
UA - Ucraina 5
JO - Giordania 4
AT - Austria 3
BE - Belgio 3
CA - Canada 3
ES - Italia 3
FR - Francia 3
JP - Giappone 3
CZ - Repubblica Ceca 1
IN - India 1
SC - Seychelles 1
Totale 2.055
Salva come PNG Salva come JPEG
Città #
Warsaw 492
Fairfield 219
Ashburn 130
Woodbridge 111
Seattle 103
Cambridge 93
Dublin 89
Chandler 86
Houston 71
Wilmington 67
Lawrence 35
Altamura 30
Ann Arbor 28
Dong Ket 26
Princeton 24
Hong Kong 22
Beijing 15
Florence 13
Bern 12
Medford 12
Boston 11
Jacksonville 11
San Diego 8
Izmir 7
Shanghai 7
Boardman 6
Buffalo 6
New York 6
Acton 3
Barcelona 3
Brussels 3
Norwalk 3
Phoenix 3
Vienna 3
Falls Church 2
Hillsboro 2
Montréal 2
Singapore 2
Tokyo 2
West Jordan 2
Andover 1
Asnieres-sur-Seine 1
Atlanta 1
Auburn Hills 1
Charlottesville 1
Ebisu 1
Gniezno 1
Kerken 1
London 1
Los Angeles 1
New Bedfont 1
Old Bridge 1
Pune 1
San Jose 1
Tappahannock 1
Toronto 1
Totale 1.786
Salva come PNG Salva come JPEG
Nome #
Hepcidin levels and their determinants in different types of myelodysplastic syndromes 221
Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis 217
Severe hypoxia selects hematopoietic progenitors with stem cell potential from primary Myelodysplastic syndrome bone marrow cell cultures. 153
Redistribution of H3K27me3 and acetylated histone H4 upon exposure to azacitidine and decitabine results in de-repression of the AML1/ETO target gene IL3. 107
Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine. 105
Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine. 103
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents 95
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine 93
Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study 90
Mutated ASXL1 and number of somatic mutations as possible indicators of progression to chronic myelomonocytic leukemia of myelodysplastic syndromes with single or multilineage dysplasia 85
Hypermethylation of Wnt antagonist gene promoters and activation of Wnt pathway in myelodysplastic marrow cells. 84
Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of myelodysplastic syndrome patients. 84
A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria. 84
Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents 80
Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of myelodysplastic syndrome patients. 79
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. 75
Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS? 69
Effects of erythropoiesis-stimulating agents on overall survival of international prognostic scoring system low/intermediate-1 risk, transfusion-inde-pendent myelodysplastic syndrome patients: A cohort study 67
ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems 65
Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis 57
Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine 48
Rapid evaluation of T cell clonality in the diagnostic work-up of mature T cell neoplasms: TRBC1-based flow cytometric assay experience 20
PIEZO1 mutations impact on early clinical manifestations of myelodysplastic syndromes 16
Totale 2.097
Salva come PNG Salva come JPEG
Categoria #
all - tutte 6.120
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.120
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019202 0 0 0 0 0 0 0 0 0 43 86 73
2019/2020481 28 34 17 37 60 54 57 61 54 29 40 10
2020/2021515 20 30 5 23 6 115 55 50 58 83 12 58
2021/2022154 4 18 5 1 6 15 5 5 6 19 21 49
2022/2023409 30 75 26 13 37 76 55 24 47 2 8 16
2023/2024137 5 21 21 6 7 32 11 27 3 4 0 0
Totale 2.097